Exelixis, Inc. (EXEL) Q1 2019 Earnings Results

Exelixis Misses on EPS, Stock Down 1.63%

Exelixis reported an EPS of $0.27, which was below expectations, leading to a stock decline of 1.63%. The lack of revenue figures and guidance may have contributed to investor uncertainty. The focus on clinical trials suggests that the company is prioritizing long-term growth over immediate financial performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.27	N/A	-7.56%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing the importance of their clinical programs. They did not provide any updates on revenue guidance.

Management did not provide specific revenue guidance for the upcoming quarters.

The company is focusing on its ongoing clinical trials and product development.

Exelixis Misses on EPS, Stock Down 1.63%

Key numbers

Management commentary

Exelixis, Inc.

More earnings this week

Exelixis Misses on EPS, Stock Down 1.63%

Key numbers

Management commentary